![]() |
市場調查報告書
商品編碼
1497871
糖尿病足潰瘍治療市場:治療方法、潰瘍類型和最終用途分類 - 全球預測 2024-2030Diabetic Foot Ulcer Treatment Market by Treatment (Antibiotic Medications, Biologics, Therapy Devices), Ulcer Type (Ischemic Ulcers, Neuro-Ischemic Ulcers, Neuropathic Ulcers), End-use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
糖尿病足潰瘍治療市場規模預計2023年為53.5億美元,2024年達56.9億美元,預計2030年將達到83.5億美元,複合年成長率為6.56%。
糖尿病足潰瘍 (DFU) 治療包括旨在預防、診斷和治療糖尿病足潰瘍的根本原因和併發症的各種服務、產品和技術。由於全球糖尿病盛行率不斷上升,以及面臨慢性傷口風險的人口老化,對糖尿病足潰瘍治療的需求正在擴大。此外,醫療保健專業人員和患者對有效 DFU 管理的認知不斷提高,也導致了晚期糖尿病足潰瘍的普及。先進 DFU 治療產品的高成本阻礙了該治療的普及並抑制了市場成長。透過生物工程皮膚替代、幹細胞療法、基於生長因子的療法和傷口護理(NPWT)等創新技術,糖尿病足潰瘍治療的技術進步預計將為市場成長創造機會。
主要市場統計 | |
---|---|
基準年[2023] | 53.5億美元 |
預測年份 [2024] | 56.9億美元 |
預測年份 [2030] | 83.5億美元 |
複合年成長率(%) | 6.56% |
區域洞察
隨著人口老化面臨慢性傷口的風險,美國人口中糖尿病的盛行率不斷增加,對糖尿病足潰瘍治療的需求也不斷擴大。據加拿大健康研究所(CIHR)稱,到2021年,將有超過300萬加拿大人,即總人口的8.8%,被診斷出患有糖尿病,其中6.1%的加拿大成年人面臨患糖尿病的高風險。墨西哥、阿根廷、巴西和智利等新興經濟體的糖尿病正在迅速蔓延,大多數糖尿病患者尚未確診。政府為改善整個歐洲 DFU 治療的可近性而採取的重大舉措預計將為市場成長奠定基礎。該地區的主要參與者正在為先進且具有成本效益的 DFU治療方法的開發做出貢獻。由於需要更好治療的糖尿病患者數量顯著增加以及人們對其管理的認知不斷提高,亞太地區的糖尿病足潰瘍市場呈現出先進的態勢。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在糖尿病足潰瘍治療市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對糖尿病足潰瘍治療市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對糖尿病足潰瘍治療市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[184 Pages Report] The Diabetic Foot Ulcer Treatment Market size was estimated at USD 5.35 billion in 2023 and expected to reach USD 5.69 billion in 2024, at a CAGR 6.56% to reach USD 8.35 billion by 2030.
The diabetic foot ulcer (DFU) treatment includes a range of services, products, and technologies designed to prevent, diagnose, and treat the underlying causes and complications of diabetic foot ulcers. The increasing prevalence of diabetes globally, coupled with an aging population at risk for chronic wounds, is expanding the need for diabetic foot ulcer treatment. Additionally, growing awareness about effective DFU management among healthcare professionals and patients is contributing to the increase in the adoption of advanced diabetic foot ulcers. High costs associated with advanced DFU treatment products hinder the widespread adoption of treatment, thereby hampering market growth. Rising technological advancements in diabetic foot ulcer treatment with innovations such as bioengineered skin substitutes, stem cell therapy, growth factor-based therapies, and negative pressure wound therapy (NPWT) are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 5.35 billion |
Estimated Year [2024] | USD 5.69 billion |
Forecast Year [2030] | USD 8.35 billion |
CAGR (%) | 6.56% |
Regional Insights
The growing prevalence of diabetes among America's population, with an aging population at risk for chronic wounds, is expanding the need for diabetic foot ulcer treatment. As per the Canadian Institutes of Health Research (CIHR), in 2021, over 3 million Canadians, or 8.8% of the population, have been diagnosed with diabetes, and 6.1% of Canadian adults were at high risk of developing diabetes. Developing economies, including Mexico, Argentina, Brazil, and Chile, observe a rapid prevalence of diabetes disorders with a majority presence of undiagnosed diabetic patients. Significant governmental efforts to improve the accessibility of DFU treatment across Europe are expected to create a platform for market growth. The key players in the region are contributing to develop advanced and cost-effective DFU treatments. The Asia-Pacific showcases an advanced landscape for the diabetic foot ulcer market owing to a significant rise in diabetic patients requiring better treatment and surging awareness regarding its management among the population.
Market Insights
The market dynamics represent an ever-changing landscape of the Diabetic Foot Ulcer Treatment Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Diabetic Foot Ulcer Treatment Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Diabetic Foot Ulcer Treatment Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Researchers develop 3D printed bandage that delivers innovative treatment for diabetic foot ulcers
Researchers at Queen's University Belfast developed a groundbreaking 3D printed bandage for the treatment of diabetic foot ulcers (DFUs). The bandage, also known as a scaffold, combines lipid nanoparticles and hydrogels to create personalized skin-like 3D printed scaffolds. These scaffolds have the ability to release antibiotic-loaded molecules in bulk and sustainably. [Published On: 2023-07-27]
Healthium launches Theruptor Novo for diabetic foot ulcers
Healthium Medtech introduced Theruptor Novo, a new wound dressing portfolio designed for the treatment of chronic wounds, such as leg ulcers and diabetic foot ulcers. This wound dressing is antimicrobial and non-toxic, incorporating patented technology that has been recognized in the U.S., India, EU, and Canada. This product effectively reduces the development of resistant microbes and promotes the healing process by utilizing a physical kill mechanism. [Published On: 2022-10-11]
Smith+Nephew announces new study showing GRAFIX Membrane cut the rate of diabetic foot ulcer recurrence in half compared to competitors
Smith+Nephew's GRAFIX Cryopreserved Placental Membrane has been proven to reduce diabetic foot ulcer recurrence rates by up to 58.5% compared to competitors, according to a study. It found a statistically significant reduction in ulcer recurrence and new ulcer formation at all time periods for GRAFIX compared to cellular and acellular CTP groups. [Published On: 2022-03-31]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Diabetic Foot Ulcer Treatment Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Diabetic Foot Ulcer Treatment Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Adocia SA, Alkem Laboratories Ltd., B. Braun SE, Cardinal Health, Inc., Centaur Pharmaceuticals Private Limited, Cipla Limited, Coloplast Corp., ConvaTec, Inc., Essity AB, GlaxoSmithKline PLC, Healthium Medtech Limited, Integra LifeSciences Corporation, Medline Industries, Inc., MIMEDX, Inc., Molnlycke Health Care AB, Organogenesis, Inc., PAUL HARTMANN AG, Pristyn Care, Reapplix A/S, SANUWAVE Health, Inc., SIGVARIS Group, Smith & Nephew PLC, SynerHeal Pharmaceuticals, Tissue Regenix Ltd., and URGO Medical, Australia Pty Ltd..
Market Segmentation & Coverage